Key takeaways
- In a retrospective, single-centre cohort of 101 patients/102 hips undergoing primary total hip arthroplasty with CATALYSTEM System, no dislocations, periprosthetic femoral fractures, mechanical failures or aseptic femoral stem revisions were reported at a median follow-up of 1.1 years1
- All stems were reported as well-fixed radiographically, with no aseptic loosening observed1
- Among patients with available paired data, mean HOOS, JR improvement was 45.3 points at one year (n=53). Incomplete follow-up means this may not represent the experience of the wider cohort1
- The findings provide an encouraging early signal, but longer follow-up and comparative evidence are needed to assess whether these outcomes are maintained
Why early evidence matters for a new cementless stem
Total hip arthroplasty is a well-established procedure, but early femoral complications remain clinically important. Cementless femoral stems require initial stability while biological fixation develops, making periprosthetic femoral fracture, loss of fixation, mechanical failure and early revision important signals to monitor.1
These questions remain clinically relevant because data from the National Joint Registry continue to identify aseptic loosening as the leading indication for hip revision, while periprosthetic fracture and infection remain important revision indications.2 As a result, fixation-related outcomes are among the key endpoints to consider when evaluating a new cementless femoral stem.
CATALYSTEM System is a triple-tapered cementless femoral stem, available with or without a collar, designed to fit a wide variety of femur types, with enhanced implant fit across multiple femoral morphologies.3,4 With a design based on Smith+Nephew’s heritage of clinically successful stems,5,6 CATALYSTEM System provides for predictable & reproducible stem seating,7,8 and is designed to address a global population.3,9
One-year evidence can provide valuable insight into early safety, fixation and recovery, while helping understand how a new implant system performs during the critical post-operative period. Although further follow-up is needed to establish long-term survivorship and evaluate the risk of late aseptic loosening, early clinical data can help determine whether a stem is performing as intended and whether any unexpected safety signals emerge. The most useful question is therefore not whether these data provide a definitive assessment of CATALYSTEM System, but what they tell us at this stage of the evidence base and how they can help build surgeon confidence.
The study at a glance
Bahlouli, et al. retrospectively evaluated patients undergoing primary, elective total hip arthroplasty with the CATALYSTEM collared stem implanted. The study was conducted at a single high-volume academic hospital, with procedures performed by six fellowship-trained arthroplasty surgeons.1
Which findings are most relevant to the stem?
The outcomes most directly relevant to the femoral component were fixation, periprosthetic femoral fracture, mechanical failure and aseptic femoral stem revision. At latest follow-up, the authors reported no periprosthetic femoral fractures, mechanical failures or aseptic femoral stem revisions. All stems were described as well-fixed radiographically, with no aseptic loosening observed.1
The relevance of these findings extends beyond this individual study. Registry evidence continues to show that aseptic loosening remains the leading indication for hip revision, while periprosthetic fracture is also an important revision indication.2 The absence of these events at one year may therefore be considered a reassuring early signal, although longer follow-up is required to determine whether these observations are maintained.
What do the patient-reported outcomes add?
HOOS, JR, a validated patient-reported outcome measure of pain, function and patient-perceived outcome after total hip arthroplasty, improved progressively among patients with available follow-up data.1
Among patients with available paired data, mean HOOS, JR improvement was 15.0 points at six weeks, 25.2 points at three months and 45.3 points at one year. HOOS, JR is widely used to assess pain, function and patient-perceived outcome following total hip arthroplasty, and the magnitude of improvement observed in this cohort suggests patients experienced meaningful functional recovery.1 However, only 53 of the 102 hips contributed paired one-year data, meaning the reported improvements may not fully represent the experience of the wider cohort.
These improvements are relevant to the overall outcome of total hip arthroplasty, but they should not be attributed solely to the femoral stem. Patient characteristics, surgical technique, the acetabular construct and the wider perioperative and rehabilitation pathway may all influence pain and functional recovery.
How should the wider recovery data be interpreted?
The study reported that 96% of patients were discharged home and that mean length of stay was 27 hours. These outcomes help describe the care pathway in which CATALYSTEM was used, but they are not direct measures of femoral stem performance. Institutional protocols, anaesthesia, surgical approach, patient selection and discharge practice may all contribute.1
Within 90 days, three patients were readmitted for surgery-related reasons: two for periprosthetic joint infection, with one requiring subsequent single-stage revision, and one for superficial wound dehiscence. These events are important for understanding the overall study experience, although infection outcomes are multifactorial.1
What questions remain unanswered?
The study provides an initial view of CATALYSTEM in clinical use, but several uncertainties remain. It was retrospective, conducted at one institution and had no comparator group. Radiographic assessment was performed by the senior author rather than through a standardised radiographic analysis, and patient-reported outcome follow-up was incomplete.1
While one-year follow-up can provide insight into early fixation and complication profiles, the NJR reports that revision timing varies by indication: infection and periprosthetic fracture generally occur earlier, whereas aseptic loosening and lysis generally occur later.2 Registry-based surveillance and continued clinical follow-up are therefore important for understanding longer-term implant performance.
Most importantly, one year is sufficient to look for early mechanical, radiographic and clinical signals, but not to establish long-term survivorship, late aseptic loosening or performance across broader practice settings. Larger cohorts, comparative evidence and continued follow-up will be needed to answer those questions.
Early evidence should answer early questions. At one year, this study provides encouraging observations for CATALYSTEM in the early post-operative period, particularly around femoral fixation and the absence of reported aseptic mechanical complications in this cohort. The findings support continued clinical evaluation, while recognising the limits of a retrospective, single-centre study with incomplete patient-reported outcome follow-up.
